Top

Published in:

01-08-2011 | Review Article

Chronic adult primary immune thrombocytopenia (ITP) in the Asia-Pacific region

Authors: Lee Lai Heng, Priscilla Caguioa, Ng Soo Chin, Tzeon-Jye Chiou, Jong Wook Lee, Yoshitaka Miyakawa, Karmel L. Tambunan, Beng H. Chong

Published in: International Journal of Hematology | Issue 2/2011

Abstract

Patients with primary immune thrombocytopenia (ITP) from the Asia-Pacific region often exhibit characteristics distinct from those of patients from the West. Moreover, as the region itself is heterogeneous, the ITP landscape among individual Asia-Pacific countries can be diverse. The recently released international consensus report on ITP places new emphasis on ITP, but does not address the unique ITP landscape in the Asia-Pacific region, which is home to 60% of the world’s population. In an attempt to characterize how the ITP landscape differs between the West and the Asia-Pacific region, an expert panel with representatives from Northeast Asia, Southeast Asia, and Australia was convened. Important differences were identified between the guidance provided in the international consensus report and experience in the Asia-Pacific region, namely diagnostic practices, incidence and approach to ITP secondary to H. pylori infection, systemic lupus erythematosus-related ITP, the use of bone marrow examination, initial treatment strategies, and the role of splenectomy, rituximab, and thrombopoietin receptor agonists.

An International Asian-Pacific ITP registry is being established based on the recommendations of this panel, with an anticipated launch in 2011.

Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113:2386–93.CrossRefPubMed

Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115:168–86.CrossRefPubMed

The United Nations Population Fund. Asia & the Pacific. Available at 149120322/asiapacific/. Accessed April 15, 2010.

Stasi R, Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clinic Proc. 2004;79:504–22.CrossRef

Cines DB, Bussel JB. How I treat idiopathic thrombocytopenia purpura (ITP). Blood. 2005;106:2244–51.CrossRefPubMed

Ng S-C, Sangkar VJ. Long term follow-up of 72 Asian adult patients with immune thrombocytopenic purpura. Int J Hematol. 2002;76:Abst O10.

Kueh YK. Adult idiopathic thrombocytopenic purpura (ITP)—a prospective tracking of its natural history. Singapore Med J. 1995;36:367–70.PubMed

Kang CM, Lee JG, Kim KS, Choi JS, Lee WJ, Kim BR, et al. Long-term follow-up of laparoscopic splenectomy in patients with immune thrombocytopenic purpura. J Korean Med Sci. 2007;22:420–4.CrossRefPubMedPubMedCentral

Chen C-C, Ho C-H, Wu T-S, Wu J-S, You J-Y, Chau W-K, et al. Predictive prognostic factors after splenectomy in patients with idiopathic thrombocytopenic purpura. Haematologica. 2001;86:663–4.PubMed

10.

Kuwana M, Kurata Y, Fujimura K, Fujisawa K, Wada H, Nagasawa T, et al. Preliminary laboratory based diagnostic criteria for immune thrombocytopenic purpura: evaluation by multi-center prospective study. J Thromb Haemost. 2006;4:1936–43.CrossRefPubMed

11.

Kurata Y, Fujimura K, Kuwana M, Tomiyama Y, Murata M. Epidemiology of primary immune thrombocytopenia in children and adults in Japan: a population-based study and literature review. Int J Hematol. 2011;93:329–35.CrossRefPubMed

12.

Stasi R, Sarpatwari A, Segal JB, Osborn J, Evangelista ML, Cooper N, et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood. 2009;113:1231–40.CrossRefPubMed

13.

Arnold DM, Bernotas A, Nazi I, Stasi R, Kuwana M, Liu Y, et al. Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review. Haematologica. 2009;94:850–6.CrossRefPubMedPubMedCentral

14.

Fujimura K. Helicobacter pylori infection and idiopathic thrombocytopenia purpura. Int J Hematol. 2005;81:113–8.CrossRefPubMed

15.

Cines DB, Bussell JB, Liebman HA, Prak ETL. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009;113:6511–21.CrossRefPubMedPubMedCentral

16.

World Gastroenterology Organisation. WGO practice guideline—Helicobacter pylori in developing countries. Available at http://www.worldgastroenterologyorg/helicobacter-pylori-in-developing-countries.html. 2006.

17.

Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol. 1998;13:1–12.CrossRefPubMed

18.

Teg BH, Lin JT, Pan WH, Lin SH, Wang LY, Lee TK, et al. Seroprevalence and associated risk factors for Helicobacter pylori infection in Taiwan. Anticancer Res. 1994;14:1389–92.

19.

Yeoh KG. Helicobacter pylori infection and its treatment in Singapore. Singapore Med J. 2000;41:4–7.

20.

Kang JY, Yeoh KG, Ho K, Guan R, Lim TP, Quak SH, et al. Racial differences in Helicobacter pylori seroprevalence in Singapore: correlation with differences in peptic ulcer frequency. J Gastroenterol Hepatol. 1997;12:655–9.CrossRefPubMed

21.

Mahadeva S, Raman MC, For AC, Follows M, Axon ATR, Goh K-L, et al. Gastro-oesophageal reflux is more prevalent in Western dyspeptics: a prospective comparison of British and South-East Asian patients with dyspepsia. Aliment Pharmacol Ther. 2005;21:1483–90.CrossRefPubMed

22.

Tan HJ, Goh KL. Changing epidemiology of Helicobacter pylori in Asia. J Dig Dis. 2008;9:186–9.CrossRefPubMed

23.

Fujimura K, Kuwana M, Kurata Y, Imamura M, Harada H, Sakamaki H, et al. Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan. Int J Hematol. 2005;81:162–8.CrossRefPubMed

24.

Ikeda Y. Revision of guidelines for diagnosis and treatment if chronic idiopathic thrombocytopenic purpura. Rinsho Ketsueki. 2004;45:421–7.PubMed

25.

Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, et al. Second Asia-Pacific consensus guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol. 2009;24:1587–600.CrossRefPubMed

26.

Hashino S, Ota S, Kobayashi S, Tanaka J, Musashi M, Fukuhara T, et al. Current status of treatment for patients with idiopathic thrombocytopenic purpura in the Hokkaido area (evaluation of Helicobacter pylori eradication). Rinsho Ketsueki. 2004;45:539–45.PubMed

27.

Jang JH, Kim HI, Lee HW, Kang SY, Park JS, Choi JH, et al. Correlation between Helicobacter pylori eradication and platelet count in immune thrombocytopenic purpura (ITP). Blood. 2005;106:Abstract 4003.

28.

Danchencko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 2006;15(5):308–18.CrossRef

29.

Thumboo J, Wee H-L. Systemic lupus erythematosus in Asia: is it more common and more severe? APLAR J Rheumatol. 2006;9:320–6.CrossRef

30.

Wong GC, Lee LH. A study of idiopathic thrombocytopenic purpura (ITP) patients over a ten-year period. Ann Acad Med Singapore. 1998;27:789–93.PubMed

31.

Shin KS, Lee JL, Cho SJ, Shin DG, Kim SK, Baek JH, et al. Long-term observation of 87 cases with chronic idiopathic thrombocytopenic purpura in adults. Korean J Hematol. 2000;35:233–40.

32.

Yoon JA, Kim CK, Kim SH, Kim KH, Kim HJ, Park SK, et al. Initial therapy with high-dose dexamethasone for patients with idiopathic thrombocytopenic purpura. Korean J Hematol. 2009;44:22–7.CrossRef

33.

Kim SY, Jang JY, Han SS, Yoon YS, Park YC, Han HS, et al. Clinical outcome and predictive factor of splenectomy in patients with idiopathic thrombocytopenia purpura. Korean J Hepatobiliary Pancreat Surg. 2005;9:113–6.

34.

Wu J-M, Lai I-R, Yuan R-H, Yu S-C. Laparoscopic splenectomy for idiopathic thrombocytopenic purpura. Am J Surg. 2004;187:720–3.CrossRefPubMed

35.

Friedman RL, Hiatt JR, Korman JL, Facklis K, Cymerman J, Phillips EH. Laparoscopic or open splenectomy for hematologic disease: which approach is superior? J Am Coll Surg. 1997;185:49–54.CrossRefPubMed

36.

Brunt LM, Langer JC, Quasebarth MA, Whitman ED. Comparative analysis of laparoscopic versus open splenectomy. Am J Surg. 1996;172:596–601.CrossRefPubMed

37.

Choi CW, Kim BS, Seo JH, Shin SW, Kim YH, Kim JS, et al. Response to high-dose intravenous immune globulin as a valuable factor predicting the effect of splenectomy in chronic idiopathic thrombocytopenic purpura patients. Am J Hematol. 2001;66:197–202.CrossRefPubMed

38.

Ojima H, Kato T, Araki K, Okamura K, Manda R, Hirayama I, et al. Factors predicting long-term response to splenectomy in patients with idiopathic thrombocytopenic purpura. World J Surg. 2006;30:553–9.CrossRefPubMed

39.

Fairweather H, Tuckfield A, Grigg A. Abbreviated dose rituximab for immune-mediated hematological disorders. Am J Hematol. 2008;83:554–7.CrossRefPubMed

40.

Zaja F, Baccarani M, Mazza P, Bocchia M, Gugliotta L, Zaccaria A, et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood. 2010;115:2755–62.CrossRefPubMed

41.

Rituxan [prescribing information]. Weston, MA and South San Francisco, CA: Biogen Idec Inc. and Genentech Inc; 2011.

42.

Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009;113:4834–40.CrossRefPubMedPubMedCentral

43.

Evens AM, Jovanovic BD, Su YC, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol. 2010; Published online November 29. doi:10.1093/annonc/mdq583.

44.

Hou J, Liu Z, Gu F. Epidemiology and prevention of hepatitis B virus infection. Int J Med Sci. 2005;2:50–7.CrossRefPubMedPubMedCentral

45.

Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2009;371:395–403.CrossRef

46.

Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357:2237–47.CrossRefPubMed

47.

Nurden AT, Viallard J-F, Nurden P. New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura. Lancet. 2009;373:1562–9.CrossRefPubMed

48.

Tomiyama Y, Miyakawa Y, Okamoto S, Katsutani S, Kimura A, Okoshi Y. Six month treatment of low dose eltrombopag is efficacious in Japanese patients with refractory chronic immune thrombocytopenic purpura (ITP). Blood (American Society of Hematology annual meeting abstracts). 2009;114:1324.

49.

Shirasugi Y, Ando K, Hashino S, Nagasawa T, Kurata Y, Kishimoto Y, et al. A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenia purpura. Int J Hematol. 2009;20:157–65.CrossRef

Title: Chronic adult primary immune thrombocytopenia (ITP) in the Asia-Pacific region
Authors: Lee Lai Heng
Priscilla Caguioa
Ng Soo Chin
Tzeon-Jye Chiou
Jong Wook Lee
Yoshitaka Miyakawa
Karmel L. Tambunan
Beng H. Chong
Publication date: 01-08-2011
Publisher: Springer Japan
Published in: International Journal of Hematology / Issue 2/2011
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-011-0894-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2011

Clinical utility of the neutrophil distribution pattern obtained using the CELL-DYN SAPPHIRE hematology analyzer for the diagnosis of myelodysplastic syndrome

Berbamine overcomes imatinib-induced neutropenia and permits cytogenetic responses in Chinese patients with chronic-phase chronic myeloid leukemia

Primary mediastinal large B-cell lymphoma (PMLBCL) in Chinese patients: clinical characteristics and prognostic factors

Genetic analysis of patients with deep vein thrombosis during pregnancy and postpartum

Deregulated transcription factors in leukemia

Pharmacokinetics-based optimal dose prediction of donor source-dependent response to mycophenolate mofetil in unrelated hematopoietic cell transplantation

Keynote webinar | Spotlight on antibody–drug conjugates in cancer